Weekly Recap: 12—month SPS durability and $500—$600K pricing plan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) reported 12—month durability and good safety for SPS in generalized myasthenia gravis with no high—grade CRS/ICANS, CEO Warner Biddle says stronger—than—expected durability supports premium pricing above $500—$600K and a 2,000—2,500 U.S. patient launch; BLA…